By: Kyle Doherty From: onclive.com Frontline treatment with ribociclib (Kisqali) in combination with endocrine therapy displayed a significant progression-free survival (PFS) benefit with superior tolerability vs combination chemotherapy in patients with clinically aggressive hormone receptor–positive, HER2-negative advanced breast cancer, according to findings from the phase 2 RIGHT Choice trial (NCT03839823) published in the Journal of Clinical Oncology. At a median …
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
Source: Novartis Pharmaceuticals Corporation From: prnewswire.com MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit demonstrated for premenopausal women as shown in MONALEESA-7(1,2) The relative risk reduction of death by 36% in the MONALEESA-3 first-line (1L) postmenopausal population highlights …
Savvy Cooperative: Paid Opportunity for People Diagnosed with Breast Cancer, currently taking Kisqali or Piqray, not living near a large city
SCREENER Eligibility Criteria: Adult who has been diagnosed with breast cancer Currently taking Kisqali or Piqray Does not live near a big city/ in an urban area NOTE: Only patients with verified diagnoses will be considered US resident Details: 60-minute virtual interview From home Receive: $100 Link: https://gigs.savvy.coop/bcancer/?r=44951 Why Sign Up? Your experiences are so valuable and important to creating …
CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer
By: Erica DiNapoli From: onclive.com Most discussion in hormone receptor (HR)–positive metastatic breast cancer are now focused on CDK4/6 inhibition, according to Denise A. Yardley, MD, who added that, after demonstrating significant survival benefits, these agents have transformed the standard of care. “There are 3 key agents: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Several phase 3 trials incorporating these …
CDK4/6 Inhibitors for Breast Cancer: Who Does, Doesn’t Benefit?
By: Nick Mulcahy From: medscape.com One of the success stories in recent years in the treatment of metastatic, hormone-receptor positive breast cancer has been the addition of drugs acting as inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) on top of endocrine therapy. Three such drugs are now available — palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Lilly). …
Novartis Kisqali significantly prolongs life in women with HR+/HER2- advanced breast cancer now in two distinct Phase III trials
In MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant improvement in overall survival in post-menopausal women in first- and second-line setting Kisqali is the only CDK4/6 inhibitor proven to prolong life with multiple combination partners These results build on the unique MONALEESA-7 data presented at ASCO 2019 showing overall survival benefit of Kisqali plus aromatase inhibitor in pre-/peri-menopausal women Full results …
Novartis reports new positive data from MONALEESA trials
From: drugdevelopment-technology.com Novartis has reported positive results from three pivotal Phase III MONALEESA trials evaluating kisqali (ribociclib) plus endocrine therapy in combination with endocrine therapy alone for the treatment of human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer in patients with difficult-to-treat visceral disease. The results are based on subgroup analyses and demonstrated that kisqali plus endocrine therapy …
Pfizer, Novartis agree UK price cuts for new breast cancer drugs
From: reuters.com Pfizer and Novartis have agreed price cuts for their rival breast cancer drugs Ibrance and Kisqali to ensure they can be used routinely within Britain’s state-funded health service. The National Institute for Health and Care Excellence (NICE), the country’s cost-effectiveness agency, said on Thursday the two drugs were being recommended despite uncertainty about how long they extend overall …